Pulmonary Drug Delivery: Novel Pharmaceutical Technologies Breathe New Life into the Lungs

Nanjwade, Basavaraj K.; Adichwal, Sagar A; Gaikwad, Kishori R.; Parikh, Kemy A.; Manvi, F. V.

doi:10.5731/pdajpst.2011.00704

Cited by 23 publications

(21 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rapid improvement in aerosol formulation and delivery devices could greatly change the landscape for therapy against lung cancer (Nanjwade et al , 2001; Gagnadoux et al , 2008). Clearly, the delivery of cytotoxins, drugs, and small molecules targeting genes or pathways to the primary tumour with minimal systemic toxicity will allow the testing of new combinatorial approaches and more intensive dose schedules.…”

Section: Discussionmentioning

confidence: 99%

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model

et al. 2013

View full text Add to dashboard Cite

Background:Epigenetic silencing by promoter methylation and chromatin remodelling affects hundreds of genes and is a causal event for lung cancer. Treatment of patients with low doses of the demethylating agent 5-azacytidine in combination with the histone deacetylase inhibitor entinostat has yielded clinical responses. The subcutaneous dosing route for consecutive days and reduced bioavailability of 5-azacytidine because of inactivation by cytidine deaminase may limit the expansion of epigenetic therapy into Phase III trials. To mitigate these barriers, an aerosol of 5-azacytidine was generated and characterised.Methods:The effect of aerosol vs systemic delivery of 5-azacytidine on tumour burden and molecular response of engrafted lung tumours in the nude rat was compared.Results:Pharmacokinetics revealed major improvement in the half-life of 5-azacytidine in lung tissue with aerosol delivery. Aerosolised 5-azacytidine significantly reduced lung tumour burden and induced global demethylation of the epigenome at one-third of the comparable effective systemic dose. High commonality for demethylation of genes was seen in tumours sampled throughout lung lobes and across treated animals receiving the aerosolised drug.Conclusion:Collectively, these findings show that aerosolised 5-azacytidine targets the lung, effectively reprogrammes the epigenome of tumours, and is a promising approach to combine with other drugs for treating lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Traditional techniques such as grinding, spray drying and with the help of more recent advances in supercritical fluid extraction procedure, precipitation, and solvent extraction methods have also been employed to produce more efficient nanoparticle formulations for the treatment of pulmonary diseases. 128,129 …”

Section: Nanomedicine As An Emerging Therapeutic Approach For Real mentioning

confidence: 99%

Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation

et al. 2013

View full text Add to dashboard Cite

The advent of nanotechnology has reignited interest in the field of pharmaceutical science for the development of nanomedicine. Nanomedicinal formulations are nanometer-sized carrier materials designed for increasing the drug tissue bioavailability, thereby improving the treatment of systemically applied chemotherapeutic drugs. Nanomedicine is a new approach to deliver the pharmaceuticals through different routes of administration with safer and more effective therapies compared to conventional methods. To date, various kinds of nanomaterials have been developed over the years to make delivery systems more effective for the treatment of various diseases. Even though nanomaterials have significant advantages due to their unique nanoscale properties, there are still significant challenges in the improvement and development of nanoformulations with composites and other materials. Here in this review, we highlight the nanomedicinal formulations aiming to improve the balance between the efficacy and the toxicity of therapeutic interventions through different routes of administration and how to design nanomedicine for safer and more effective ways to improve the treatment quality. We also emphasize the environmental and health prospects of nanomaterials for human health care.

show abstract

“…DPIs are propellant free, portable, easy to use and cost-effective devices. Moreover, DPIs are activated by the inspiration effort of patients, allowing a rapid and higher dose administration and a more efficient pulmonary drug deposition [22,23]. Thus, DPIs are currently considered the most convenient and suitable alternative for inhaling anti-TB drugs [24].…”

Section: Particulate Carriers As Inhalable Delivery Systemsmentioning

confidence: 99%

Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery

Miranda

Rodrigues

Domingues

et al. 2018

Materials Science and Engineering: C

View full text Add to dashboard Cite

The growing interest on polymeric delivery systems for pulmonary administration of drugs anticipates a more direct and efficient treatment of diseases such as tuberculosis (TB) that uses the pulmonary route as the natural route of infection. Polymeric microparticles or nano-in-microparticles offer target delivery of drugs to the lungs and the potential to control and sustain drug release within TB infected macrophages improving the efficiency of the anti-TB treatment and reducing side effects. In a dry powder form these inhalable delivery systems have increased stability and prolonged storage time without requiring refrigeration, besides being cost-effective and patient convenient. Thus, this review aims to compile the recent innovations of inhalable polymeric dry powder systems for the delivery of anti-TB drugs exploring the methods of production, aerodynamic characterization and the efficacy of targeted drug delivery systems using in vitro and in vivo models of the disease. Advanced knowledge and promising outcomes of these systems are anticipated to simplify and revolutionize the pulmonary drug delivery and to contribute towards more effective anti-TB treatments.

show abstract

Pulmonary Drug Delivery: Novel Pharmaceutical Technologies Breathe New Life into the Lungs

Cited by 23 publications

References 87 publications

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model

Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation

Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery

Contact Info

Product

Resources

About